Greater Glasgow and Clyde Medicines

Restrictions:

The use as monotherapy or in combination with methotrexate, for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying anti-rheumatic drug therapy has been inadequate, is restricted to specialist use in patients with active psoriatic arthritis who have failed on, or are unsuitable for, treatment with an anti-TNF drug

Prescribing Notes:

For use in psoriasis, see section 13.5.3 and use in Crohn's disease, see section 1.5.3.

BNF Link

Restrictions:

Restricted to specialist use in accordance with the prescribing notes below.

Prescribing Notes:

Psoriasis in adults:

• The treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systematic therapies including ciclosporin, methotrexate and psoralen and UVA treatment (PUVA) is restricted to specialist use. Continued treatment should be restricted to patients who achieve a PASI 75% response within 16 weeks.

Psoriasis in adolescents:

• The treatment of moderate to severe plaque psoriasis in adolescent patients from the age of 12 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies is restricted to specialist use.  Continued treatment should be restricted to patients who achieve at least 75% improvement in their Psoriasis Area and Severity Index (PASI 75) within 16 weeks.

For use in psoriatic arthritis see section 10.1.3 and for use in Crohn's disease see section 1.5.3

BNF Link

Restrictions:

Crohn's disease:

• The treatment of adults with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or where intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist or have medical contraindications to such therapies is restricted to specialist use in accordance with NHSGGC protocol.

Ulcerative Colitis:

• The treatment of adults with moderately to severely active ulcerative colitis who have had a inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies is restricted to specialist use.

Link to relevant NHSGGC clinical guidelines

Prescribing Notes:

For uses in rheumatology, see section 10.1.3 and for usese in dermatology see section 13.5.3

BNF Link